GlaxoSmithKline

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Established: 1929-01-01

Employees: 70.2K

Market Cap: $90B

Website: http://www.gsk.com

Introduction: GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials

Study to Assess Safety & Immunogenicity of GSK Biologicals' Boostrix (dTpa) Vaccine vs. Chinese DT Vaccine

Phase 3

Completed

Conditions: Diphtheria
Acellular Pertussis
Tetanus

First Posted Date: 2007-03-27

Last Posted Date: 2016-10-28

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 660

Registration Number: NCT00452686

Locations: 🇨🇳
GSK Investigational Site, Suining, China

TRX4 Monoclonal Antibody in Type 1 Diabetes (T1 DM)

Phase 2

Terminated

Conditions: Diabetes Mellitus, Type 1

Interventions: Drug: Otelixizumab

First Posted Date: 2007-03-23

Last Posted Date: 2017-11-13

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 88

Registration Number: NCT00451321

Locations: 🇨🇦
GSK Investigational Site, Toronto, Ontario, Canada

Bioequivalence And Effect Of Food And Water On Lamotrigine in Healthy Volunteers

Phase 1

Completed

Conditions: Mental Disorders

Interventions: Drug: Lamotrigine ODT tablets
Drug: Lamotrigine IR tablets

First Posted Date: 2007-03-21

Last Posted Date: 2017-08-08

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 220

Registration Number: NCT00449774

Locations: 🇺🇸
GSK Investigational Site, Dallas, Texas, United States

A Study To Assess The Pharmacokinetics Of Different Modified Release Formulations Of GSK221149 In Healthy Adult Subjects

Phase 1

Terminated

Conditions: Obstetric Labour, Premature
Premature Ejaculation

First Posted Date: 2007-03-21

Last Posted Date: 2012-03-19

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 36

Registration Number: NCT00449709

Locations: 🇺🇸
GSK Investigational Site, Tacoma, Washington, United States

Assess Consistency of Immunogenicity of GlaxoSmithKline Biologicals' Pandemic Influenza Vaccine (GSK1562902A) in Adults

Phase 3

Completed

Conditions: Influenza
Influenza Vaccines

Interventions: Biological: H5N1 adjuvanted split virus vaccine (A/Vietnam/1194/2004 strain)
Biological: H5N1 non-adjuvanted split virus vaccine (A/Vietnam/1194/2004 strain)
Biological: H5N1 adjuvanted split virus vaccine (A/Indonesia/05/2005 strain)